4594 BrightPath Biotherapeutics Co., Ltd. - Financial Results

4594

TSE Growth

BrightPath Biotherapeutics Co., Ltd.

Result

JPY

-1

(-2.22%)

Jun 12, 3:30 pm JST

0.27

USD

Jun 12, 2:30 am EDT

PER

ー

PBR

2.60

Yield

ー%

Margin Trading Ratio

13.42

PTS

outside of trading hours

44.1

Jun 12, 11:58 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Currency: JPY

Annual

Result

Guidance History

Growth Rate

Profitability

Record-high

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	5M	-1,467M	-1,473M	-1,485M	-24.9	0	May 12, 2023	J-GAAP
Mar, 2024	0M	-1,155M	-1,158M	-1,168M	-18.2	0	May 10, 2024	J-GAAP
Mar, 2025	1M	-1,160M	-1,147M	-1,151M	-14.1	0	May 9, 2025	J-GAAP
Mar, 2026	0M	-1,295M	-1,293M	-1,304M	-11.7	0	May 14, 2026	J-GAAP
Guidance Mar, 2027	0M	-1,965M	-1,947M	-1,949M	-14.0	0	May 14, 2026	J-GAAP
YoY	－	-51.7%	-50.6%	-49.5%	-19.9%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2022 Initial Forecast	May 13, 2021	2M	-1,852M	-1,852M	-1,854M	0	J-GAAP
Revised	Mar 30, 2022	17M	-1,852M	-1,852M	-1,854M	0	J-GAAP
Results	May 12, 2022	15M	-1,476M	-1,481M	-1,484M	0	J-GAAP
Mar, 2023 Initial Forecast	May 12, 2022	Available in future release
Results	May 12, 2023
Mar, 2024 Initial Forecast	May 12, 2023
Revised	Jan 26, 2024
Results	May 10, 2024
Mar, 2025 Initial Forecast	May 10, 2024
Revised	Mar 24, 2025
Results	May 9, 2025
Mar, 2026 Initial Forecast	May 9, 2025
Revised	Mar 13, 2026
Results	May 14, 2026
Mar, 2027 Initial Forecast	May 14, 2026	0M	-1,965M	-1,947M	-1,949M	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2011	117M	－	Available in future release
Mar, 2012	194M	+65.8
Mar, 2013	451M	+132.5
Mar, 2014	933M	+106.9
Mar, 2015	821M	-12.0
Mar, 2016	822M	+0.1
Mar, 2017	529M	-35.6
Mar, 2018	354M	-33.1
Mar, 2019	155M	-56.2
Mar, 2020	11M	-92.9
Mar, 2021	2M	-81.8
Mar, 2022	15M	+650.0
Mar, 2023	5M	-66.7
Mar, 2024	0M	-100.0
Mar, 2025	1M	－
Mar, 2026	0M	-100.0
Guidance Mar, 2027	0M	－	-1,965M	-51.7	-1,947M	-50.6	-14.0	-19.7

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2025	1M	-1,160M	-116,000	-123.83	-97.96	ー	-14.1
Mar, 2026	0M	-1,295M	ー	-80.22	-70.03	ー	-11.7
Guidance Mar, 2027	0M	-1,965M	ー	-83.01	-74.85	ー	-14.0

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	933M	-27M	219M	217M	1,821.9
Fiscal Year	Mar, 2014	Mar, 2014	Mar, 2013	Mar, 2013	Mar, 2013

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2023	0M	-550M	-551M	-553M	-8.8	0	Nov 10, 2023	J-GAAP
Apr - Sep, 2024	0M	-542M	-537M	-538M	-7.1	0	Nov 8, 2024	J-GAAP
Apr - Sep, 2025	0M	-464M	-460M	-462M	-4.5	0	Nov 14, 2025	J-GAAP
Guidance Apr - Sep, 2026	ー	ー	ー	ー	－	0	May 14, 2026	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Sep, 2023 Initial Forecast	May 12, 2023	ー	ー	ー	ー	0	J-GAAP
- - - - Results	Nov 10, 2023	0M	-550M	-551M	-553M	0	J-GAAP
Sep, 2024 Initial Forecast	May 10, 2024	Available in future release
Results	Nov 8, 2024
Sep, 2025 Initial Forecast	May 9, 2025
Results	Nov 14, 2025
Sep, 2026 Initial Forecast	May 14, 2026	ー	ー	ー	ー	0	J-GAAP

Cash Flow

Currency: JPY

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2024	-1,155M	-1,163M	-1,156M	-7M	690M	1,057M	85.93	J-GAAP
Mar, 2025	-1,160M	-1,251M	-1,250M	-1M	1,004M	810M	72.32	J-GAAP
Mar, 2026	-1,295M	-1,366M	-1,365M	-1M	2,713M	2,156M	82.80	J-GAAP

Actual Performance and Financial Trends

Currency: JPY

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	0M	-1,155M	-1,158M	-1,168M	-18.2	0	May 10, 2024	J-GAAP
Mar, 2025	1M	-1,160M	-1,147M	-1,151M	-14.1	0	May 9, 2025	J-GAAP
Mar, 2026	0M	-1,295M	-1,293M	-1,304M	-11.7	0	May 14, 2026	J-GAAP
YoY	－	-11.6%	-12.7%	-13.3%	+17.1%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	0M	-326M	-329M	-330M	-4.7	-Inf	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	0M	-216M	-208M	-208M	-2.8	-Inf	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	0M	-273M	-275M	-277M	-3.5	-Inf	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	1M	-345M	-335M	-336M	-4.1	-34,500.0	May 9, 2025	J-GAAP
Apr - Jun, 2025	0M	-245M	-240M	-241M	-2.6	-Inf	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	0M	-219M	-220M	-221M	-2.2	-Inf	Nov 14, 2025	J-GAAP
Oct - Dec, 2025	0M	-492M	-492M	-493M	-4.7	-Inf	Feb 13, 2026	J-GAAP
Jan - Mar, 2026	0M	-339M	-341M	-349M	-3.1	-Inf	May 14, 2026	J-GAAP
YoY	－	+1.7%	-1.8%	-3.9%	+24.0%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Apr - Jun, 2021	0M	－	Available in future release
Jul - Sep, 2021	0M	-100.0
Oct - Dec, 2021	0M	－
Jan - Mar, 2022	15M	+1,400.0
Apr - Jun, 2022	0M	－
Jul - Sep, 2022	0M	－
Oct - Dec, 2022	5M	－
Jan - Mar, 2023	0M	-100.0
Apr - Jun, 2023	0M	－
Jul - Sep, 2023	0M	－
Oct - Dec, 2023	0M	-100.0
Jan - Mar, 2024	0M	－
Apr - Jun, 2024	0M	－
Jul - Sep, 2024	0M	－
Oct - Dec, 2024	0M	－
Jan - Mar, 2025	1M	－
Apr - Jun, 2025	0M	－
Jul - Sep, 2025	0M	－
Oct - Dec, 2025	0M	－
Jan - Mar, 2026	0M	-100.0	-339M	+1.7	-341M	-1.8	-3.1	+24.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	209M	-180M	-190M	-190M	-2.2
Fiscal Year	Sep, 2015	Dec, 2015	Jun, 2016	Jun, 2016	Sep, 2025

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2024	13.52	77.7	1,230M	956M	-2,653M	0.12	May 10, 2024	J-GAAP
Mar, 2025	9.98	80.6	1,120M	903M	-3,804M	0.03	May 9, 2025	J-GAAP
Mar, 2026	16.91	90.2	2,604M	2,348M	-5,109M	ー	May 14, 2026	J-GAAP

BrightPath Biotherapeutics Co., Ltd.(4594) Financial Results